Other Pharmaceuticals - Chad

Chad

The Other Pharmaceuticals market in Chad is projected to generate a revenue of US$15.74m in 2024.
It is expected to experience an annual growth rate (CAGR 2024-2029) of 3.32%, leading to a market volume of US$18.53m by 2029.
In terms of global comparison, United States will contribute the highest revenue with US$260.50bn in 2024.
Chad's market for other pharmaceuticals is experiencing a surge in demand due to increased healthcare awareness and government initiatives.

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for pharmaceutical products has been on the rise in Chad in recent years. This trend is driven by several factors such as population growth, improved healthcare access, and rising incomes.

Customer preferences: Chadian consumers tend to prefer generic drugs due to their affordability compared to branded products. Additionally, there is a preference for locally produced medicines, as they are perceived to be of higher quality and more reliable.

Trends in the market: The pharmaceutical market in Chad is dominated by imported products, with the majority of drugs coming from France and India. However, there has been a recent push by the Chadian government to increase local production of pharmaceuticals, which has led to the establishment of several local manufacturing companies. This trend is expected to continue as the government seeks to reduce reliance on imported products and boost local economic growth.

Local special circumstances: Chad is a landlocked country, which presents logistical challenges for the importation of pharmaceutical products. This has led to supply chain issues and occasional shortages of certain drugs. Additionally, the country has a high burden of infectious diseases such as malaria, which has driven demand for antimalarial drugs and other related products.

Underlying macroeconomic factors: Chad is one of the poorest countries in the world, with a large portion of the population living below the poverty line. However, the country has experienced some economic growth in recent years, driven by its oil industry. This growth has led to rising incomes and increased demand for healthcare services and products. Despite this growth, the healthcare system in Chad remains underfunded and understaffed, which has limited access to healthcare services for many Chadians.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.